Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Krankenhaus Nord, 3500 Vienna, Austria.
Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione G. Pascale"-IRCCS, 80131 Napoli, Italy.
Future Oncol. 2020 Dec;16(34):2799-2808. doi: 10.2217/fon-2020-0740. Epub 2020 Aug 28.
Final overall survival (OS) and time on treatment analysis of patients with mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. NCT03370770 (ClinicalTrials.gov).
接受序贯阿法替尼和奥希替尼治疗的 突变阳性非小细胞肺癌（NSCLC）患者的最终总生存（OS）和治疗时间分析。患者（n=203）在一线阿法替尼治疗后出现 T790M 阳性疾病，并在数据录入前至少 10 个月开始奥希替尼治疗。主要结局是治疗时间；OS 分析是探索性的。阿法替尼和奥希替尼的中位治疗时间为 27.7 个月（90%CI：26.7-29.9）。中位 OS 为 37.6 个月（90%CI：35.5-41.3）；Del19 阳性患者和亚洲患者的中位 OS 分别为 41.6 个月和 44.8 个月。在真实世界的临床实践中，序贯阿法替尼和奥希替尼治疗 突变阳性 NSCLC 患者的结局令人鼓舞，尤其是 Del19 阳性患者和亚洲患者。NCT03370770（ClinicalTrials.gov）。
